Danaher Corp
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
No hay suficientes datos históricos para mostrar el gráfico de DHR.
Precio
$ 6.135
Var. %
+2,59%
Volumen operado
14.174
Precio DHR
US$ 208,74
Teórico (precio / ratio)
DHR ÷ 54
US$ 3,87
Sí, existe el CEDEAR de DHR (Danaher Corp) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es DHR.
El ticker del CEDEAR de Danaher Corp en Argentina es DHR. La acción subyacente cotiza en NYSE con el símbolo DHR.
El CEDEAR DHR tiene un ratio de 54:1. Eso significa que 54 CEDEARs equivalen a 1 acción de DHR.
El CEDEAR DHR cotiza hoy a $ 6.135 en pesos argentinos, con una variación diaria de +2,59%.
La acción subyacente DHR (Danaher Corp) cotiza a US$ 208,74 en su mercado de origen (NYSE).
Yahoo · 15 de sept de 2026
The global single-use bioreactors market is forecast to grow from USD 5.43 billion in 2026 to USD 9.58 billion by 2031, at a 12.0% CAGR. Growth is driven by bio…
SeekingAlpha · 10 de sept de 2026
Third Pointâs Q2 2026 13F: portfolio doubled to $4.68B as WBD becomes top holding; new buys include Keysight, Block; exits Meta/Nvidia. See more here.
Yahoo · 10 de sept de 2026
Danaher currently trades at $204.89 per share and has shown little upside over the past six months, posting a middling return of 5%. The stock also fell short o…
Cotización
US$ 3,87
vs teórico
+0,12%
Cotización MEP implícita
$ 1.585,27
Cotización
US$ 3,57
vs teórico
-7,77%
Cotización Cable implícita
$ 1.720,9
El precio teórico del CEDEAR DHR se calcula dividiendo el precio de DHR por el ratio (54). Hoy resulta en US$ 3,87.
En BYMA podés operar DHR en pesos, DHRD en dólar MEP y DHRC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR DHR en pesos argentinos, con datos de data912.
Yahoo · 9 de sept de 2026
Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re
Yahoo · 8 de sept de 2026
A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag alrea…
Yahoo · 8 de sept de 2026
500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recomb…
SeekingAlpha · 8 de sept de 2026
Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.
Noticias vía Finnhub